{"created":"2023-05-15T14:48:24.417524+00:00","id":66329,"links":{},"metadata":{"_buckets":{"deposit":"b17033d5-397d-4157-92a3-1a22b0fb5bef"},"_deposit":{"created_by":1,"id":"66329","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"66329"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00066329","sets":["10:29"]},"author_link":["652625","652627","652628","652629","652630","652632","652631","652623","652626","652624","652622","652621"],"item_10005_date_7":{"attribute_name":"発表年月日","attribute_value_mlt":[{"subitem_date_issued_datetime":"2017-05-13","subitem_date_issued_type":"Issued"}]},"item_10005_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Purpose: To determine the prognostic factors for biochemical recurrence (BR) and mortality in patients with high-risk localized prostate cancer after carbon-ion radiotherapy (CIRT) combined with long-term androgen deprivation therapy (LTADT).\nMethods and Materials: A total of 1247 patients were enrolled in three phase II clinical trials of fixed-dose CIRT between 2000 and 2013. Excluding T4 disease, 614 patients received CIRT combined with LTADT for high- or very-high-risk disease, according to the National Comprehensive Cancer Network (NCCN) classification system. \nResults: Median follow-up time was 78.7 months, and 5-year rates of BR-free, prostate cancer-specific survival, and overall survival were 90.4% (95% confidence interval [CI]: 87.6 - 92.7), 98.5% (95% CI: 97.2 - 99.2), and 94.7% (95% CI: 92.8 - 96.5), respectively. T3a/b disease, Gleason score (GS) 9-10, percentage of positive biopsy cores (PPCs) > 75%, and age > 75 years had a significant impact on BR. Moreover, patients with T3b disease, GS 9-10, and PPCs > 75% had significantly higher prostate cancer-specific mortality (p = 0.007, p = 0.009, and p = 0.015, respectively) and overall mortality (p = 0.035, p = 0.025, and p < 0.001, respectively), on multivariate analyses.\nConclusions: Prognostic factors for BR and mortality were identified. Patients with T3b disease, GS 9-10, and PPCs > 75% should be considered to have very-high-risk disease requiring a new treatment strategy.","subitem_description_type":"Abstract"}]},"item_10005_description_6":{"attribute_name":"会議概要（会議名, 開催地, 会期, 主催者等）","attribute_value_mlt":[{"subitem_description":"the 56th Annual Conference of the Particle Therapy Co-operative Group (PTCOG56)  ","subitem_description_type":"Other"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Kasuya, Goro"}],"nameIdentifiers":[{"nameIdentifier":"652621","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Ishikawa, Hitoshi"}],"nameIdentifiers":[{"nameIdentifier":"652622","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Tsuji, Hiroshi"}],"nameIdentifiers":[{"nameIdentifier":"652623","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Makishima, Hirokazu"}],"nameIdentifiers":[{"nameIdentifier":"652624","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Nomiya, Takuma"}],"nameIdentifiers":[{"nameIdentifier":"652625","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kamada, Tadashi"}],"nameIdentifiers":[{"nameIdentifier":"652626","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"粕谷 吾朗","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"652627","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"石川 仁","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"652628","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"辻 比呂志","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"652629","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"牧島 弘和","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"652630","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"野宮 琢磨","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"652631","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"鎌田 正","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"652632","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"conference object","resourceuri":"http://purl.org/coar/resource_type/c_c94f"}]},"item_title":"Prognostic Factors in High-Risk Prostate Cancer after Carbon-Ion Radiotherapy Combined with Long-Term Androgen Deprivation Therapy","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Prognostic Factors in High-Risk Prostate Cancer after Carbon-Ion Radiotherapy Combined with Long-Term Androgen Deprivation Therapy"}]},"item_type_id":"10005","owner":"1","path":["29"],"pubdate":{"attribute_name":"公開日","attribute_value":"2017-05-23"},"publish_date":"2017-05-23","publish_status":"0","recid":"66329","relation_version_is_last":true,"title":["Prognostic Factors in High-Risk Prostate Cancer after Carbon-Ion Radiotherapy Combined with Long-Term Androgen Deprivation Therapy"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T20:50:10.432079+00:00"}